NASDAQ:AMRN Amarin (AMRN) Stock Forecast, Price & News $1.26 +0.02 (+1.61%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$1.22▼$1.3150-Day Range$1.16▼$1.5452-Week Range$1.04▼$2.23Volume2.35 million shsAverage Volume3.72 million shsMarket Capitalization$508.83 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Amarin MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside98.4% Upside$2.50 Price TargetShort InterestHealthy5.20% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.15) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 starsMedical Sector732nd out of 981 stocksPharmaceutical Preparations Industry351st out of 459 stocks 3.3 Analyst's Opinion Consensus RatingAmarin has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, Amarin has a forecasted upside of 98.4% from its current price of $1.26.Amount of Analyst CoverageAmarin has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.20% of the outstanding shares of Amarin have been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Amarin has recently decreased by 12.84%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMRN. Previous Next 2.0 News and Social Media Coverage News SentimentAmarin has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amarin this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for AMRN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Amarin to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.81% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 31.94% of the stock of Amarin is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amarin (NASDAQ:AMRN) StockAmarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.Read More Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Stock News HeadlinesJune 4, 2023 | fool.comAmarin Plc (NASDAQ: AMRN)June 1, 2023 | finanznachrichten.deAmarin Corporation plc: Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland ChinaJune 7, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 1, 2023 | finance.yahoo.comAmarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland ChinaMay 20, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Amarin (NASDAQ:AMRN)May 12, 2023 | marketwatch.comAmarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa(R)/Vazkepa(R) (Icosapent Ethyl) Reduction of Cardiovascular EventsMay 12, 2023 | finance.yahoo.comAmarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular EventsMay 10, 2023 | msn.comAmarin Corp's Return On Capital Employed InsightsJune 7, 2023 | UNKNOWN (Ad)The Stock That's Brining Lithium Back To America!The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S SoilMay 9, 2023 | msn.comAlkermes board declines to endorse any Sarissa nomineesMay 6, 2023 | americanbankingnews.comAmarin Co. plc (NASDAQ:AMRN) Receives $2.38 Consensus Price Target from BrokeragesMay 3, 2023 | finance.yahoo.comAmarin's (AMRN) Q1 Earnings Top, Vascepa Sales FallMay 3, 2023 | finance.yahoo.comAmarin Plc (AMRN) Q1 2023 Earnings Call TranscriptMay 2, 2023 | finance.yahoo.comBiotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & MoreMay 1, 2023 | americanbankingnews.comAmarin (AMRN) Scheduled to Post Quarterly Earnings on WednesdayApril 21, 2023 | americanbankingnews.comAmarin Co. plc (NASDAQ:AMRN) Sees Significant Increase in Short InterestApril 20, 2023 | americanbankingnews.comShort Interest in Amarin Co. plc (NASDAQ:AMRN) Grows By 17.6%April 19, 2023 | finance.yahoo.comAmarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023April 19, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Amarin Co. plc's Q1 2023 Earnings (NASDAQ:AMRN)April 17, 2023 | finanznachrichten.deAmarin Corporation plc: Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O'Connor to Company's Board of DirectorsApril 17, 2023 | benzinga.comAmarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O'Connor to Company's Board of DirectorsApril 17, 2023 | finance.yahoo.comAmarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of DirectorsApril 16, 2023 | seekingalpha.comAmarin: Sarissa Has Control, But Amarin Will Need PatienceApril 13, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn SituationApril 11, 2023 | americanbankingnews.comFinancial Contrast: Amarin (NASDAQ:AMRN) versus Rain Oncology (NASDAQ:RAIN)April 11, 2023 | americanbankingnews.comAnalysts Set Amarin Co. plc (NASDAQ:AMRN) Price Target at $2.38April 8, 2023 | americanbankingnews.comAmarin (NASDAQ:AMRN) versus Aeterna Zentaris (NASDAQ:AEZS) Critical ContrastSee More Headlines AMRN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMRN Company Calendar Last Earnings11/03/2021Today6/06/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMRN CUSIPN/A CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees560Year Founded1991Price Target and Rating Average Stock Price Forecast$2.50 High Stock Price Forecast$3.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+98.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,800,000.00 Net Margins-25.16% Pretax Margin-24.95% Return on Equity-15.45% Return on Assets-10.00% Debt Debt-to-Equity RatioN/A Current Ratio2.80 Quick Ratio1.88 Sales & Book Value Annual Sales$369.19 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book0.86Miscellaneous Outstanding Shares403,830,000Free Float368,252,000Market Cap$508.83 million OptionableOptionable Beta1.78 Social Links Key ExecutivesAaron D. BergPresident & Chief Executive OfficerDerek KalinowskiSVP-Manufacturing OperationsThomas ReillyChief Financial Officer & SVPSteven B. KetchumChief Scientific Officer & Executive VPNabil A. AbadirChief Medical Officer-Global Medical AffairsKey CompetitorsNurix TherapeuticsNASDAQ:NRIXJanux TherapeuticsNASDAQ:JANXAlpine Immune SciencesNASDAQ:ALPNStoke TherapeuticsNASDAQ:STOKArcutis BiotherapeuticsNASDAQ:ARQTView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 30,000 shares on 6/1/2023Ownership: 0.007%Ameriprise Financial Inc.Bought 30,600 shares on 5/22/2023Ownership: 0.324%JPMorgan Chase & Co.Bought 11,443 shares on 5/18/2023Ownership: 0.007%State Street CorpBought 1,558,604 shares on 5/16/2023Ownership: 0.474%Susquehanna International Group LLPSold 529,000 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AMRN Stock - Frequently Asked Questions Should I buy or sell Amarin stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRN shares. View AMRN analyst ratings or view top-rated stocks. What is Amarin's stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month target prices for Amarin's shares. Their AMRN share price forecasts range from $2.00 to $3.00. On average, they predict the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 98.4% from the stock's current price. View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts. How have AMRN shares performed in 2023? Amarin's stock was trading at $1.21 at the beginning of 2023. Since then, AMRN stock has increased by 4.1% and is now trading at $1.26. View the best growth stocks for 2023 here. Are investors shorting Amarin? Amarin saw a drop in short interest in May. As of May 15th, there was short interest totaling 20,980,000 shares, a drop of 12.8% from the April 30th total of 24,070,000 shares. Based on an average daily trading volume, of 3,200,000 shares, the days-to-cover ratio is currently 6.6 days. View Amarin's Short Interest. When is Amarin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our AMRN earnings forecast. How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The biopharmaceutical company earned $142 million during the quarter, compared to analysts' expectations of $161.29 million. Amarin had a negative net margin of 25.16% and a negative trailing twelve-month return on equity of 15.45%. Amarin's revenue for the quarter was down 8.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.02) earnings per share. What ETFs hold Amarin's stock? ETFs with the largest weight of Amarin (NASDAQ:AMRN) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Global X Aging Population ETF (AGNG), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), What is John Thero's approval rating as Amarin's CEO? 43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX). What is Amarin's stock symbol? Amarin trades on the NASDAQ under the ticker symbol "AMRN." Who are Amarin's major shareholders? Amarin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Two Sigma Investments LP (1.38%), DG Capital Management LLC (1.36%), Sarissa Capital Management LP (1.22%), 13D Management LLC (1.03%), Acadian Asset Management LLC (0.82%) and Two Sigma Advisers LP (0.71%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum. View institutional ownership trends. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amarin's stock price today? One share of AMRN stock can currently be purchased for approximately $1.26. How much money does Amarin make? Amarin (NASDAQ:AMRN) has a market capitalization of $508.83 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. How many employees does Amarin have? The company employs 560 workers across the globe. Does Amarin have any subsidiaries? The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.Read More How can I contact Amarin? Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com. This page (NASDAQ:AMRN) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.